FDA Inspection 1229889 — SPI Pharma, Inc.
The FDA completed an inspection of SPI Pharma, Inc. on February 1, 2024 in Lewes, DE. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 1, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Lewes, DE (United States)